Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
COMBAT-SAB
COMBAT-SAB: Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
1 other identifier
interventional
2,096
1 country
13
Brief Summary
The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which are positive for a certain type of bacteria.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4
Started Feb 2026
Typical duration for phase_4
13 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 21, 2026
CompletedFirst Posted
Study publicly available on registry
January 29, 2026
CompletedStudy Start
First participant enrolled
February 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2029
January 29, 2026
January 1, 2026
2.9 years
January 21, 2026
January 26, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Desirability of Outcome Ranking (DOOR)
The DOOR ordinal scale includes four possible outcomes: treatment failure, infectious complications, antibiotic-associated adverse events and death. The ordinal scale comprises five levels: levels 1-4 are defined by survival at 30 days and the presence of either none, one, two or three of three possible outcomes; level 5 indicates death before 30 days. A DOOR analysis estimates the probability that overall outcomes in any given subject in one group are overall superior to those in a random subject from the other treatment group; probabilities \>50% reject the null hypothesis.
From enrollment to 30 days post enrollment
Secondary Outcomes (10)
90-day hospital-free days alive
From enrollment to 90 days after enrollment
30-day all cause mortality
From enrollment to 30 days after enrollment
90-day all-cause mortality
From enrollment to 90 days after enrollment
30-day bacteremia-free days
From enrollment to 30 days after enrollment
Length of stay
Measured at the time of hospital discharge, up to 30 days after enrollment
- +5 more secondary outcomes
Study Arms (2)
Patients with methicillin-sensitive S. aureus bacteremia (MSSAB)
EXPERIMENTALPatients with methicillin-sensitive S. aureus bacteremia (MSSAB) will be assigned to one of two different antibiotic treatment strategies appropriate for MSSA: 1) antibiotic monotherapy, or 2) combination antibiotic therapy
Patients with methicillin-resistant S. aureus bacteremia (MRSAB)
EXPERIMENTALPatients with methicillin-resistant S. aureus bacteremia (MRSAB) will be assigned to one of two different antibiotic treatment strategies appropriate for MRSA: 1) antibiotic monotherapy, or 2) combination antibiotic therapy
Interventions
Intravenous anti-staphylococcal beta-lactam, either cefazolin or nafcillin, per the discretion of the treating physician.
Vancomycin or daptomycin, per discretion of the treating physician
Patients with methicillin-sensitive S. aureus bacteremia (MSSAB) and no contraindications will receive an anti-staphylococcal beta-lactam, either cefazolin or nafcillin, plus ertapenem
Daptomycin plus ceftaroline
Eligibility Criteria
You may qualify if:
- Age ≥18 years
- Alive and admitted to an Intermountain Health (IH) hospital acute care unit at enrollment
- Initial positive blood culture with either methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-susceptible Staphylococcus aureus (MSSA), collected:
- on or during the index admission to an IH hospital, or
- in an ambulatory setting (laboratory, clinic or emergency department) within 48 hours of the index admission, or
- at a non-IH network hospital within 24 hours of subsequent transfer to an IH hospital
You may not qualify if:
- Patient requests that patient health data not be included in the analysis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (13)
Platte Valley Hospital
Brighton, Colorado, 80601, United States
Saint Joseph Hospital
Denver, Colorado, 80218, United States
St. Mary's Regional Hospital
Grand Junction, Colorado, 81501, United States
Good Samaritan Hospital
Lafayette, Colorado, 80026, United States
Lutheran Medical Center
Wheat Ridge, Colorado, 80401, United States
St. Vincent Regional Hospital
Billings, Montana, 59101, United States
St. James Hospital
Butte, Montana, 59701, United States
Holy Rosary Hospital
Miles City, Montana, 59301, United States
Intermountain Medical Center
Murray, Utah, 84107, United States
McKay-Dee Hospital
Ogden, Utah, 84403, United States
Utah Valley Hospital
Provo, Utah, 84604, United States
LDS Hospital
Salt Lake City, Utah, 84143, United States
St. George Regional Hospital
St. George, Utah, 84790, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Brandon J Webb, MD
Intermountain Health Care, Inc.
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor of Research, Division of Infectious Diseases
Study Record Dates
First Submitted
January 21, 2026
First Posted
January 29, 2026
Study Start
February 1, 2026
Primary Completion (Estimated)
January 1, 2029
Study Completion (Estimated)
January 1, 2029
Last Updated
January 29, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will share
- Time Frame
- Data sharing will be available six months after anticipated enrollment completion, estimated August 2029, for a period to be determined by the Intermountain Office of Research and IRB
- Access Criteria
- Will be determined on an individual basis, upon request to the IH Office of Research.
In order to protect patient privacy and comply with relevant regulations, identified data will be unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org